Five Prime (FPRX)

Company Description

Five Prime is a leader in the discovery of innovative protein therapeutics.

We have developed a library of more than 5,700 human extracellular proteins, which we believe represent substantially all of the body’s medically important targets for protein therapeutics.

Building on this expertise in protein science, we have developed proprietary high-throughput protein screening technologies that we use to identify new targets for protein therapeutics in relatively short periods of time. As a result, we have built a pipeline of novel product candidates for cancer and inflammatory diseases.

Our drug discovery platform has also made us a sought-after discovery and development partner. To date we have generated over $262 million from collaborations with partners, including Bristol-Myers Squibb, GlaxoSmithKline and UCB Pharma.

Our strategy is to be opportunistic in our development programs. Pursuing clinical development of our product candidates both independently and in collaborations allows us to enhance the capital resources needed to strengthen our core technology and expand our product pipeline.

 

COMPANY ADDRESS
Two Corporate Drive
South San Francisco, CA 94080
United States

COMPANY PHONE
415-365-5600

COMPANY WEBSITE


Get BioInvest's perspective on Five Prime’s CEO

Latest Company News

Hot Stocks Report: Five Prime Therapeutics, Inc. (FPRX), Tailored Brands, Inc ... Post Analyst - 4 hours ago Five Prime Therapeutics, Inc. (FPRX) has made its way to a 12-month decline of -18.31%. Turning to Tailored Brands, Inc. (NYSE:TLRD), its shares were trading at $10.07 a gain of $0.08, on the trading floor. [...]
Tue, Jun 27, 2017 5:37:00 PM, Continue reading at the source
Somewhat Positive News Coverage Very Likely to Affect Five Prime Therapeutics ... The Cerbat Gem - Jun 26, 2017 Five Prime Therapeutics logo Media coverage about Five Prime Therapeutics (NASDAQ:FPRX) has been trending somewhat positive recently, Accern Sentiment Analysis reports. Five Prime Therapeutics, Inc. (NASDAQ:FPRX) Moves 11.10% Over the Past 5 Days - Concord Register State Board of Administration of Florida Retirement System Has $577000 Stake ... - BNB Daily (blog) [...]
Mon, Jun 26, 2017 6:33:00 PM, Continue reading at the source
Five Prime Therapeutics founder, CEO to step down MarketWatch - Jun 21, 2017 Biotech company Five Prime Therapeutics, Inc. FPRX, -0.70% said late Wednesday founder and Chief Executive Lewis T. "Rusty" Williams plans leave his post and become executive chairman of the board by next year. Five Prime Therapeutics Announces Lewis T. “Rusty” Williams Plans to ... - GlobeNewswire (press release) Were Analysts Bearish Five Prime Therapeutics Inc (NASDAQ:FPRX) This Week? - Weekly Register [...]
Wed, Jun 21, 2017 8:26:00 PM, Continue reading at the source
Protagonist Therapeutics Appoints Five Prime Therapeutics CEO, Lewis T. "Rusty ... PR Newswire (press release) - Jun 8, 2017 NEWARK, Calif., June 8, 2017 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq: PTGX) today announced the appointment of Lewis T. "Rusty" Williams, M.D. PROTAGONIST THERAPEUTICS, INC. - StreetInsider.com [...]
Thu, Jun 08, 2017 12:00:00 PM, Continue reading at the source
Five Prime Therapeutics Presents Initial Clinical Trial Data from Phase 1/2 ... GlobeNewswire (press release) - Jun 4, 2017 SOUTH SAN FRANCISCO, Calif., June 04, 2017 (GLOBE NEWSWIRE) -- Five Prime Therapeutics, Inc. (Nasdaq:FPRX) announced that a poster featuring initial clinical data from the ongoing Phase 1/2 clinical trial of cabiralizumab in patients with PVNS was ... [...]
Sun, Jun 04, 2017 1:06:00 PM, Continue reading at the source
Five Prime Therapeutics Presents Updated Data From Phase 1 Trial of Single ... GlobeNewswire (press release) - Jun 3, 2017 SOUTH SAN FRANCISCO, Calif., June 03, 2017 (GLOBE NEWSWIRE) -- Five Prime Therapeutics, Inc. (Nasdaq:FPRX) announced that a poster featuring updated data from the ongoing Phase 1 trial of FPA144 was presented today at the 2017 American ... [...]
Sat, Jun 03, 2017 1:06:00 PM, Continue reading at the source
Five Prime Therapeutics (FPRX) Announces Updated Data From Phase 1 Trial of ... StreetInsider.com - Jun 3, 2017 Five Prime Therapeutics, Inc. (NASDAQ: FPRX) announced that a poster featuring updated data from the ongoing Phase 1 trial of FPA144 was presented today at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. [...]
Sat, Jun 03, 2017 12:56:00 PM, Continue reading at the source
Five Prime Therapeutics At An Attractive Entry Level Seeking Alpha - May 12, 2017 Five Prime Therapeutics (NASDAQ:FPRX) has suffered a rather dramatic decline in share price from its high of $60.98 in mid-November to its current levels in the high $20s. [...]
Fri, May 12, 2017 10:52:00 PM, Continue reading at the source
Five Prime Therapeutics: Initiating Coverage With A Buy Rating And A $56 Price ... Seeking Alpha - Mar 31, 2017 Five Prime Therapeutics (FPRPX) is a San Francisco-based immune-oncology company that is developing novel monoclonal antibodies for the treatment of various cancers. [...]
Fri, Mar 31, 2017 1:13:00 AM, Continue reading at the source
Five Prime At Lows With Looming Catalysts Seeking Alpha - Mar 27, 2017 Company has a diversified pipeline with several promising clinical candidates, a validating partnership with Bristol-Myers Squibb, and a large cash position. [...]
Mon, Mar 27, 2017 4:18:00 PM, Continue reading at the source